AL-амилоидоз после коронавирусной инфекции с острым нетипичным поражением сердца

Появление эффективной терапии AL-амилоидоза с поражением сердца ставит перед  специалистом задачу комплексной оценки риска  внезапной сердечной смерти (ВСС ) и ее профилактики. К этой проблеме следует подходить индивидуально и рассматривать возможность имплантации ИКД пациентам с желудочковыми нарушениями ритма: частой экстрасистолией и неустойчивой желудочковой тахикардией. При развитии нарушений ритма и проводимости у больных с амилоидозом следует иметь в виду возможность присоединения миокардита, а у пациентов, перенесших новую коронавирусную инфекцию, — ее возможную роль в индукции как постковидного миокардита, так и собственно амилоидоза.

1. Rapezzi C., Merlini G., Quarta C.C. et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009;120(13):1203–1212.

2. Жданова Е.А., Рамеев В.В., Моисеев С.В. и др. Амилоидоз сердца. Клин. фармакол. и тер. 2011;20(5):44–50.

3. Liao R., Jain M., Teller P., Connors L.H., Ngoy S., Skinner M., Falk R.H., Apstein C.S. Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation. 2001;104(14):1594–7. Erratum in: Circulation. 2013;128(11):e174. PMID: 11581134.

4. Badar T., Cornelison A.M., Shah N.D. et al. Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement. Eur. J. Haematol. 2016;97(4):342–347.

5. Damy T., Jaccard A., Guellich A. et al. Identification of prognostic markers in transthyretin and AL cardiac amyloidosis. Amyloid. 2016;23(3):194–202.

6. Seth P., Sarkar N. A comprehensive mini-review on amyloidogenesis of different SARS-CoV-2 proteins and its effect on amyloid formation in various host proteins. 3 Biotech. 2022;12(11):322. DOI: 10.1007/s13205-022-03390-1. Epub 2022 Oct 13. PMID: 36254263; PMCID: PMC9558030.

7. Olivera E., Sáez A., Carniglia L., Caruso C., Lasaga M., Durand D. Alzheimer’s disease risk after COVID-19: a view from the perspective of the infectious hypothesis of neurodegeneration. Neural. Regen Res. 2023;18(7):1404–1410. DOI: 10.4103/1673-5374.360273. PMID: 36571334.

8. Aksenova A.Y., Likhachev I.V., Grishin S.Y., Galzitskaya O.V. The Increased Amyloidogenicity of Spike RBD and pH-Dependent Binding to ACE2 May Contribute to the Transmissibility and Pathogenic Properties of SARS-CoV-2 Omicron as Suggested by In Silico Study. Int. J. Mol. Sci. 2022;23(21):13502. DOI: 10.3390/ijms232113502. PMID: 36362302; PMCID: PMC9655063.

9. Blagova O., Lutokhina Y., Kogan E., Kukleva A., , Ainetdinova D., Novosadov V., Rud` R., Savina P., Zaitsev A., Fomin V. Chronic biopsy proven post-COVID myoendocarditis with SARS-Cov-2 persistence and high level of antiheart antibodies. Clin. Cardiol. 2022;45:952–959. DOI: 10.1002/clc.23886

10. Siegismund C.S., Escher F., Lassner D., Kühl U., Gross U., Fruhwald F., Wenzel P., Münzel T., Frey N., Linke R.P., Schultheiss H.P. Intramyocardial inflammation predicts adverse outcome in patients with cardiac AL amyloidosis. Eur. J. Heart Fail. 2018;20(4):751–757. DOI: 10.1002/ejhf.1039

11. Lim H.E., Pak H.N., Kim Y.H. Acute myocarditis associated with cardiac amyloidosis manifesting as transient complete atrioventricular block and slow ventricular tachycardia. Int. J. Cardiol. 2006;109(3):395–7. DOI: 10.1016/j.ijcard.2005.05.043

12. Hartnett J., Jaber W., Maurer M., Sperry B., Hanna M., Collier P., Patel D.R., Wazni O.M., Donnellan E. Electrophysiological Manifestations of Cardiac Amyloidosis: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2021;3(4):506–515. DOI: 10.1016/j.jaccao.2021.07.010. PMID: 34729522; PMCID: PMC8543134

13. Frustaci A., Letizia C., Adamo F., Grande C., Verardo R., Chimenti C. A-V block as presentation of cardiac amyloid: prominent infiltration of conduction tissue revealed by endomyocardial biopsy. Amyloid. 2017;24(2):131–132. DOI: 10.1080/13506129.2017.1323735

14. Takano R., Ueda N., Okada A., Matsumoto M., Ikeda Y., Hatakeyama K., Izumi C., Kusano K. Fat biopsy from a pocket of cardiac implantable electronic device: An alternative diagnostic option for cardiac amyloidosis. Heart Rhythm Case Rep. 2022;8(8):554–557. DOI: 10.1016/j.hrcr.2022.05.008. PMID: 35996711; PMCID: PMC9391401.

15. Givens R.C., Russo C., Green P., Maurer M.S. Comparison of cardiac amyloidosis due to wild-type and V122I transthyretin in older adults referred to an academic medical center. Aging health. 2013;9(2):229–235. DOI: 10.2217/ahe.13.10. PMID: 24073013; PMCID: PMC3780445.

16. Donnellan E., Wazni O.M., Saliba W.I., Hanna M., Kanj M., Patel D.R., Wilner B., Kochar A., Jaber W.A. Prevalence, Incidence, and Impact on Mortality of Conduction System Disease in Transthyretin Cardiac Amyloidosis. Am. J. Cardiol. 2020;128:140–146. DOI: 10.1016/j.amjcard.2020.05.021. Epub 2020 May 16. PMID: 32650908.

17. Pericet-Rodriguez C., López-Aguilera J., Durán-Torralba C., Castillo-Dominguez JC., Ruiz-Ortiz M., Perea-Armijo J., Delgado-Ortega M., Mesa-Rubio D., González-Manzanares R., Ruiz de Castroviejo J., Martín-Dorado E., Gallo-Fernández I., López-Baizán J., Pastor-Wulf D., Rodriguez-Almodovar A., Pan Álvarez-Osorio M., Anguita-Sánchez M. Electrocardiographic features and need for pacemaker in cardiac amyloidosis: Analysis of 58 cases. Med. Clin. (Barc). 2022;159(2):78–84. English, Spanish. DOI: 10.1016/j.medcli.2021.09.022

18. Ohara T., Murata H., Yodogawa K., Yasutake M. Long-Term Electrocardiographic Follow-Up of a Patient with Light-Chain Cardiac Amyloidosis. J. Nippon Med. Sch. 2022;89(1):119–125. DOI: 10.1272/jnms.JNMS.2022_89-111

19. Boldrini M., Salinaro F., Mussinelli R., Raimondi A., Alogna A., Musca F., Palladini G., Merlini G. , Perlini S. Prevalence and Prognostic Value of Conduction Disturbances at the Time of Diagnosis of Cardiac AL Amyloidosis. Annals of Noninvasive Electrocardiology. 2013;4(18):327–335. DOI: 10.1111/anec.12032.

20. Pattanshetty D.J., Bhat P.K., Chamberlain W.A., Lyons M.R. Isolated cardiac involvement in primary amyloidosis: presenting as sick sinus syndrome and heart failure. Tex. Heart Inst. J. 2013;40(5):615–618. PMID: 24391340; PMCID: PMC3853805.

21. Ogano M., Takano H., Fukuma N., Takayama M., Takano T., Miyagi Y., Ochi M., Shimizu K., Kitamura H. Sudden death in a case of cardiac amyloidosis immediately after pacemaker implantation for complete atrioventricular block. J. Nippon. Med. Sch. 2005;72(5):285–289. DOI: 10.1272/jnms.72.285. PMID: 16247228.

22. Dispenzieri A., Gertz MA., Kyle R.A., Lacy M.Q., Burritt M.F., Therneau T.M. et al. Serum cardiac troponins and N-terminal probrain natriuretic peptide: a staging system for primary systemic amyloidosis. J. Clin. Oncol. 2004;22(18):3751–7. DOI: 10.1200/JCO.2004.03.029. PMID: 15365071

23. D’Errico S., Mazzanti A., Baldari B., Maiese A., Frati P., Fineschi V. Sudden death in lambda light chain AL cardiac amyloidosis: a review of literature and update for clinicians and pathologists. Int. J. Clin. Exp. Pathol. 2020;13(7):1474–1482. PMID: 32782665; PMCID: PMC7414507.

24. Dubrey S.W., Cha K., Anderson J., Chamarthi B., Reisinger J., Skinner M., Falk R.H. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement., QJM. International Journal of Medicine. 1998;91(2):141–157, DOI: 10.1093/qjmed/91.2.141

25. Badar T., Cornelison A.M., Shah N.D. et al. Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement. Eur. J. Haematol. 2016;97(4):342–347.

26. Zeppenfeld K., Tfelt-Hansen J., de Riva M., Winkel B.G., Behr E.R., Blom N.A. et al. ESC Scientific Document Group, 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Developed by the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC) Endorsed by the Association for European Paediatric and Congenital Cardiology (AEPC), European Heart Journal. 2022;43(40):3997–4126. DOI: 10.1093/eurheartj/ehac262

27. Kristen A.V., Dengler T.J., Hegenbart U., Schonland S.O., Goldschmidt H., Sack F.U. et al. Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm. 2008;5(2):235–40. DOI: 10.1016/j.hrthm.2007.10.016

28. Liżewska-Springer A., Sławiński G., Lewicka E. Arrhythmic Sudden Cardiac Death and the Role of Implantable Cardioverter-Defibrillator in Patients with Cardiac Amyloidosis-A Narrative Literature Review. J. Clin. Med. 2021;10(9):1858. DOI: 10.3390/jcm10091858. PMID: 33922892; PMCID: PMC8123220.

29. Palladini G., Malamani G., Cò F., Pistorio A., Recusani F., Anesi E., Garini P., Merlini G. Holter monitoring in AL amyloidosis: prognostic implications. Pacing Clin. Electrophysiol. 2001;24(8 Pt 1):1228–33. DOI: 10.1046/j.1460-9592.2001.01228.x. PMID: 11523608

30. Harmon D., Algalarrondo V., Gandjbakhch E., Extramiana F., Marijon E., Elbaz N. et al. Outcome and incidence of appropriate implantable cardioverter-defibrillator therapy in patients with cardiac amyloidosis. Int. J. Cardiol. 2016;222:562–568. DOI: 10.1016/j.ijcard.2016.07.254

31. Fontana M., Pica S., Reant P., Abdel-Gadir A., Treibel T.A., Bany persad S.M. et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2015;132(16):1570–1579. DOI: 10.1161/CIRCULATIONAHA.115.016567

32. Kotecha T., Martinez-Naharro A., Treibel T.A., Francis R., Nordin S., Abdel-Gadir A. et al. Myocardial edema and prognosis in amyloidosis. J. Am. Coll. Cardiol. 2018;71(25):2919–2931. DOI: 10.1016/j.jacc.2018.03.536. PMID: 29929616.

33. Zampieri M., Allinovi M., Olivotto I., Antonioli E., Gabriele M., Argirò A. et al. Ventricular tachyarrhythmias and sudden cardiac death in light-chain amyloidosis: a clash of cardio-toxicities? Br. J. Haematol. 2021;193(4):e27–e31. DOI: 10.1111/bjh.17399